Clinical trials are scientific studies that involve people. Most clinical trials test how effective a new potential drug, medical device, or medical technique is at improving signs or symptoms of a particular condition OR prolonging the life of a patient with the condition. Clinical trials involve a strong collaboration between researchers, drug-makers/pharmaceutical companies, hospitals, patients, and doctors.
If you have questions about what is involved in a clinical trial, check out our clinical trial FAQ.
Ongoing Clinical Trials
There are several clinical trials in process right now that support research for GBS, CIDP, and variants. Please note that this information is intended to help patients be aware of all of their options; the Foundation is unable to endorse any clinical trials.
Clinical Trials for People Currently Experiencing CIDP
-
Emnergize CIDP Clinical Trial
Emnergize CIDP Clinical Trial The Emnergize study is designed to evaluate how the investigational study drug* may work (also known as efficacy) and how safe it is for the use in adults living with CIDP. This study will evaluate the clinical study drug compared to a placebo. *The investigational study drug, empasiprubart, is not approved
-
The AMPLIFI CIDP clinical study
The AMPLIFI CIDP clinical study The AMPLIFI study is evaluating the safety and effectiveness of a new investigational drug called IMVT-1402, administered as weekly subcutaneous (SC) injections using an autoinjector in people with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Why is this clinical study being done? Antibodies are molecules in the blood that are produced to
-
Emvigorate CIDP Clinical Trial
The Emvigorate study is designed to evaluate how the investigational study drug* may work (also known as efficacy) and how safe it is for the use in adults living with CIDP. This study will evaluate the investigational study drug compared to the current standard-of-care intravenous immunoglobulin (IVIg). *The investigational study drug, empasiprubart, is not approved
-
The CASCA STUDY
The CASCA Study is evaluating an investigational drug called TAK-411 as a potential treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Why? Although there are available CIDP therapies, disease outcomes and response to treatment can be different. There is a need to develop alternative therapies that may lower patient burden. The CASCA Study researchers are looking
-
THE MIgGRATE STUDY
The MIgGRATE Study is evaluating an investigational immunoglobulin G (IgG) drug called TAK-881 as a potential treatment for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). TAK-881 is a subcutaneous IgG treatment with a higher IgG concentration than HYQVIA®, which will allow for a smaller amount of the IgG Treatment to be administered under the skin. TAK-881 has
-
CAPTIVATE: A Clinical Trial for Patients with CIDP
CAPTIVATE: A Clinical Trial for Patients with CIDP What is this trial about? The CAPTIVATE study is testing a new medicine called DNTH103 to see if it can help people with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). What is CIDP? CIDP is a rare condition where your body’s defense system (immune system) mistakenly attacks the protective
-
Phase 2 Study of IV NVG-2089 in CIDP Patients
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, and Efficacy ofIntravenous NVG-2089 in Participants with Chronic Inflammatory DemyelinatingPolyneuropathy (CIDP) The purpose of the study is to evaluate the safety of NVG-2089 and to evaluate how well patients respond to this investigational treatment. NVG-2089 is a new drug that is being developed for treating
-
Pediatric CIDP Patients for a Clinical Research Study
Has Your Child been diagnosed with CIDP? Octapharma is seeking Pediatric patients for a clinical research study (NGAM-11) to access two different IVIg doses in the treatment of CIDP For US Audience Only Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease where the body’s natural defenses, like antibodies, attack the covering of the nerves,
-
Vitalize, CIDP Clinical Trial
VITALIZE (EFC18156) A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (VITALIZE) The purpose of the study is to evaluate effects and safety of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment
-
Mobilize Clinical Trial for CIDP
Mobilize Clinical Trial for CIDP MOBILIZE (EFC17236) A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not Work (MOBILIZE) The purpose of this Phase 3 study is to test the effects and safety of riliprubart compared to placebo in adult
Clinical Trials for People Currently Experiencing GBS
-
International Guillain-Barré Syndrome Outcome Study (IGOS) Clinical Trial
International Guillain-Barré Syndrome Outcome Study (IGOS) The international GBS Outcome Study (IGOS) is the largest and longest prospective trial designed to collect extensive data from patients afflicted with GBS in a systematic manner. The aim is to collect information from patients by intensive international collaboration. All patients are followed at standard intervals from the earliest
Clinical Trials for People Currently Experiencing MMN
-
MOMENTUM CLINICAL TRIAL
For US Audience Only A Study to Evaluate Safety, Tolerability, Pharmacometrics, and Efficacy of DNTH103 in Adultswith Multifocal Motor Neuropathy (MOMENTUM) What is this trial about? The MOMENTUM study is testing a new medicine called DNTH103 to see if it can help people withMMN (Multifocal Motor Neuropathy). What is MMN? This can cause: About the
-
Help Develop a meaningful MMN-Specific Measure
Do you have Multifocal Motor Neuropathy (MMN)? Clinical Outcomes Solutions, a healthcare research company, is conducting research about the experience of living with MMN. We are looking for adults with MMN to help fine-tune an MMN-specific patient reported outcome measure (PRO) that can be used in clinical trials and clinical settings. The newly designed PRO
-
Empassion Study for MMN
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Empasiprubart Versus Intravenous Immunoglobulin in Adults with Multifocal Motor Neuropathy A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults with Multifocal Motor Neuropathy (Empassion) The main purpose of this study is to compare empasiprubart and IVIg in
